-葡萄糖共载体-2抑制使缺血性心肌中的代谢障碍正常化
Christopher Stone1, Dwight D Harris1, Mark Broadwin1
1Division of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert Medical School of Brown University, Providence, Rhode Island.
The Journal of surgical research
|October 22, 2024
概括
-葡萄糖共传输体-2 抑制剂 (SGLT2i) 在缺血性心脏病的猪模型中改善了心脏功能. 然而,代谢综合征削弱了这些好处,突出了对疾病特定模型的需求.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共传输体-2 抑制剂 (SGLT2i) 显示出心力衰竭的益处,但缺乏对缺血性心脏病的研究.
- 慢性冠状动脉疾病和代谢综合征 (MS) 对心脏治疗提出了独特的挑战.
研究的目的:
- 在慢性冠状动脉疾病和MS的大型动物模型中研究SGLT2i的血液动力学和代谢作用.
- 在这些条件下评估SGLT2i对心肌性能和组织代谢的影响.
主要方法:
- 建立了一个猪模型,用于高脂肪饮食诱导的MS和手术诱导的冠状动脉疾病.
- 动物接受了标准或高脂肪饮食,并接受了SGLT2i (canagliflozin) 或安慰剂治疗.
- 治疗后分析了血液动力学参数,心肌 perfusion 和组织分子标记.
主要成果:
- SGLT2i显著改善了心脏输出和喷射率,增加了心肌 perfusion 和毛细血管密度.
- 这些改善在患有多发性硬化症的动物中显著减弱.
- 观察到心肌组织的代谢调节,关键代谢酶的表达变化.
结论:
- 在冠状动脉疾病模型中,SGLT2i显示出显著的心脏益处.
- 心肌组织的代谢调节可能是这些改善的基础.
- 多发性硬化症的麻木效应强调了使用与疾病相关的模型用于临床翻译的重要性.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
527
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
527
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
161
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
161
01:55Secondary Active Transport
118.0K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
118.0K
01:27Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
710
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
710
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176